PolyNovo (PNV) told investors at the Bell Potter Healthcare Conference that its business is growing beyond burns. The company reported FY 2026 product sales of AUD 138.4 million, up 16.7 percent, and underlying EBITDA of AUD 13.4 million, up about 50 percent. Management said this was the third consecutive year of positive underlying EBITDA.
Group product sales rose 21.3 percent in constant currency. Operating cash flow improved by AUD 20 million year over year, and free cash flow came in at AUD 9.4 million. Gross margins remained above 90 percent. Management said EBITDA grew faster than revenue, which it described as operating leverage.
PolyNovo said its NovoSorb products have treated more than 130,000 patients in 50 countries. Its U.S. hospital network expanded by 200 hospitals in FY 2026, to 880. MTX, launched about two years ago, grew 90 percent year over year from a lower base. Nearly 300 U.S. accounts now use MTX, and many also increase their BTM use.
U.S. sales from non-burn indications grew 52.8 percent over the three-year period reviewed. The company estimates its broader patient population for trauma, surgical reconstruction and limb salvage is three to four times larger than burns alone. Management said large burn cases are infrequent and unpredictable, which makes diversification important.
PolyNovo said it expects to submit its U.S. premarket approval application for full-thickness burns ahead of its previously indicated year-end timing. It also plans to launch NovoSorb SynPath into the U.S. outpatient market, where the company said reimbursement disruption occurred during FY 2026. Management said it is studying site economics and reimbursement before expanding more broadly.
The report notes that PolyNovo shares were trading at $0.20, near their 52-week low of $0.19, and down 25 percent year to date. The source attributes to InvestingPro an analysis that the stock appears overvalued relative to its Fair Value.